106,434 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Bought by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC bought a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 106,434 shares of the company's stock, valued at approximately $2,320,000. Dianthus Therapeutics comprises about 1.9% of Ally Bridge Group NY LLC's holdings, making the stock its 25th biggest position. Ally Bridge Group NY LLC owned 0.36% of Dianthus Therapeutics at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. R Squared Ltd bought a new position in Dianthus Therapeutics during the fourth quarter worth about $26,000. KLP Kapitalforvaltning AS acquired a new position in Dianthus Therapeutics during the fourth quarter valued at approximately $33,000. KBC Group NV bought a new stake in shares of Dianthus Therapeutics in the fourth quarter worth about $35,000. AlphaQuest LLC boosted its stake in Dianthus Therapeutics by 273.1% in the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock worth $91,000 after purchasing an additional 3,072 shares during the period. Finally, Intech Investment Management LLC acquired a new position in Dianthus Therapeutics during the fourth quarter worth $201,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded down $0.16 during mid-day trading on Wednesday, reaching $19.79. 70,370 shares of the company's stock traded hands, compared to its average volume of 264,216. The business has a 50-day simple moving average of $19.85 and a 200 day simple moving average of $22.57. The stock has a market cap of $635.81 million, a P/E ratio of -7.94 and a beta of 1.48. Dianthus Therapeutics, Inc. has a 1-year low of $13.37 and a 1-year high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on DNTH shares. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Guggenheim reissued a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of "Buy" and an average target price of $54.33.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.